BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Astrocytoma AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Diagnosis
266 results:

  • 1. Glioblastoma Therapy: Past, Present and Future.
    Obrador E; Moreno-Murciano P; Oriol-Caballo M; López-Blanch R; Pineda B; Gutiérrez-Arroyo JL; Loras A; Gonzalez-Bonet LG; Martinez-Cadenas C; Estrela JM; Marqués-Torrejón MÁ
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473776
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma.
    Lim-Fat MJ; Iorgulescu JB; Rahman R; Bhave V; Muzikansky A; Woodward E; Whorral S; Allen M; Touat M; Li X; Xy G; Patel J; Gerstner ER; Kalpathy-Cramer J; Youssef G; Chukwueke U; McFaline-Figueroa JR; Nayak L; Lee EQ; Reardon DA; Beroukhim R; Huang RY; Bi WL; Ligon KL; Wen PY
    Clin Cancer Res; 2024 Apr; 30(7):1327-1337. PubMed ID: 38252427
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Analysis of Histomorphologic/Molecular Association and Immune Checkpoint Regulators in Epithelioid Glioblastoma and Pleomorphic Xanthoastrocytoma: Are These Tumors Potential Candidates for Immune Checkpoint Blockade?
    Mahajan S; Singh J; Dandapath I; Jha P; Chaturvedi S; Ahuja A; Bhardwaj M; Saran R; Garg A; Sharma MC; Manjunath N; Suri A; Sarkar C; Suri V
    Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):84-95. PubMed ID: 38158760
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. "De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade.
    Hadad S; Gupta R; Oberheim Bush NA; Taylor JW; Villanueva-Meyer JE; Young JS; Wu J; Ravindranathan A; Zhang Y; Warrier G; McCoy L; Shai A; Pekmezci M; Perry A; Bollen AW; Phillips JJ; Braunstein SE; Raleigh DR; Theodosopoulos P; Aghi MK; Chang EF; Hervey-Jumper SL; Costello JF; de Groot J; Butowski NA; Clarke JL; Chang SM; Berger MS; Molinaro AM; Solomon DA
    Acta Neuropathol; 2023 Dec; 147(1):3. PubMed ID: 38079020
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Genetic alterations that deregulate RB and PDGFRA signaling pathways drive tumor progression in IDH2-mutant astrocytoma.
    Tateishi K; Miyake Y; Nakamura T; Iwashita H; Hayashi T; Oshima A; Honma H; Hayashi H; Sugino K; Kato M; Satomi K; Fujii S; Komori T; Yamamoto T; Cahill DP; Wakimoto H
    Acta Neuropathol Commun; 2023 Nov; 11(1):186. PubMed ID: 38012788
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. General Clinico-Pathological Characteristics in Glioblastomas in Correlation with p53 and Ki67.
    Sipos TC; Kövecsi A; Ovidiu-Ioan Ș; Zsuzsánna P
    Medicina (Kaunas); 2023 Oct; 59(11):. PubMed ID: 38003967
    [No Abstract]    [Full Text] [Related]  

  • 7. Practice of IDH1, ATRX, and p53 Immunohistochemistry in Integrated diagnosis of Adult Diffuse Gliomas: Single Center Study.
    Shabanzadeh Nejabad Z; Mabroukzadeh Kavari H; Saffar H; Tavangar SM; Sefidbakht S; Khoshnevisan A; Zare-Mirzaie A; Vasei M; Jafari E; Yaghmaii M; Saffar H
    Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):390-398. PubMed ID: 37278280
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Identification of genomic biomarkers and their pathway crosstalks for deciphering mechanistic links in glioblastoma.
    Quddusi DM; Bajcinca N
    IET Syst Biol; 2023 Aug; 17(4):143-161. PubMed ID: 37277696
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With Glioma.
    Benusiglio PR; Elder F; Touat M; Perrier A; Sanson M; Colas C; Guerrini-Rousseau L; Tran DT; Trabelsi N; Carpentier C; Marie Y; Adam C; Bernier M; Cazals-Hatem D; Mokhtari K; Tran S; Mathon B; Capelle L; Dhooge M; Idbaih A; Alentorn A; Houillier C; Dehais C; Hoang-Xuan K; Cuzzubbo S; Carpentier A; Duval A; Coulet F; Bielle F
    JCO Precis Oncol; 2023 May; 7():e2200525. PubMed ID: 37262394
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis.
    Lee K; Kim SI; Kim EE; Shim YM; Won JK; Park CK; Choi SH; Yun H; Lee H; Park SH
    Sci Rep; 2023 Apr; 13(1):6761. PubMed ID: 37185778
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Exploration of NPC2 as a Potential Biomarker for Immunotherapy Using RNA-seq and Protein Data - A New Hypothesis.
    Lu W; Li D; Tao F; Chen Q; Fan S; Ma Y; Dong H; Hu Y; Yue C
    Endocr Metab Immune Disord Drug Targets; 2023; 23(10):1340-1353. PubMed ID: 37056065
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. [Diffuse midline glioma with H3K27 alteration in adults: a clinicopathological analysis].
    Yang QY; Li MN; Chen TY; Liu C; Li X; Shi ZM; Pan MH
    Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):376-383. PubMed ID: 36973199
    [No Abstract]    [Full Text] [Related]  

  • 13. Signaling Pathways in the Relapse of Glioblastoma.
    Orozco-Mera J; Peralta-Pizza F; Escobar-Vidarte O; Coll-Tello B; Ariza A
    Oncology (Williston Park); 2023 Mar; 37(3):107-117. PubMed ID: 36961958
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Clinical, histological, and molecular features of gliomas in adults with neurofibromatosis type 1.
    Romo CG; Piotrowski AF; Campian JL; Diarte J; Rodriguez FJ; Bale TA; Dahiya S; Gutmann DH; Lucas CG; Prichett L; Mellinghoff I; Blakeley JO
    Neuro Oncol; 2023 Aug; 25(8):1474-1486. PubMed ID: 36840626
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Genomic profiling and prognostic factors of H3 K27M-mutant spinal cord diffuse glioma.
    Chai RC; Yan H; An SY; Pang B; Chen HY; Mu QH; Zhang KN; Zhang YW; Liu YQ; Liu X; Zhao Z; Jiang T; Wang YZ; Jia WQ
    Brain Pathol; 2023 Jul; 33(4):e13153. PubMed ID: 36751054
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. [Report of Multidisciplinary Treatment for Sisters with Li-Fraumeni Syndrome].
    Suzuki O; Amano K; Chika N; Yamano T; Eguchi H; Nakashima H; Ooya S; Okazaki Y; Mochiki E; Takahashi T; Ishida H
    Gan To Kagaku Ryoho; 2022 Dec; 49(13):1947-1949. PubMed ID: 36733053
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Clinical and genomic features in patients with second primary glioblastoma following first primary renal cell carcinoma.
    Zhang GT; Liu Q; Zuo FX; Liu HJ; Wang SQ; Yuan Q; Liu AS; Hu K; Meng XL; Wang WJ; Qian HP; Wan JH; Cai HQ
    BMC Cancer; 2023 Jan; 23(1):104. PubMed ID: 36717819
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Polymorphisms in
    Morais de Castro E; Barbosa LV; Simoneti Fonseca A; Nagashima S; Busatta Vaz de Paula C; Zeni R; Panini do Carmo LA; Cavalli LR; Bleggi Torres LF; Senff Ribeiro A; de Noronha L; Machado-Souza C
    ASN Neuro; 2023; 15():17590914231153481. PubMed ID: 36714975
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Tumor Microenvironment and Microvascular Density in Human Glioblastoma.
    Tamma R; Ingravallo G; Annese T; d'Amati A; Lorusso L; Ribatti D
    Cells; 2022 Dec; 12(1):. PubMed ID: 36611806
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Investigation of serum E-Cadherin, VEGF121, Survivin, Tenascin C and Tetraspanin 8 levels in patients with glioblastoma.
    Tunckale T; Caliskan T; Potoglu B; Engin T; Guzel S; Celikkol A; Yilmaz A; Oznur M
    Bratisl Lek Listy; 2023; 124(4):304-308. PubMed ID: 36598325
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 14.